Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

126.65USD
26 Jul 2016
Change (% chg)

-- (--)
Prev Close
$126.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,836,373
52-wk High
$205.29
52-wk Low
$110.56

Latest Key Developments (Source: Significant Developments)

Alexion Pharmaceuticals Inc raises FY 2014 guidance - Conference Call
Thursday, 23 Oct 2014 10:00am EDT 

Alexion Pharmaceuticals Inc:Raises FY 2014 revenue guidance to the higher rage to $2.220 billion to $2.225 billion.Raises FY 2014 guidance for non-GAAP EPS to the higher range of $5.15 to $5.20, reflecting ongoing financial discipline and the operational benefits of global structure.FY 2014 revenue of $2.201 billion and EPS of $5.02 - Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals Inc submits NDA in Japan for Asfotase Alfa as treatment for patients with Hypophosphatasia
Wednesday, 15 Oct 2014 06:30am EDT 

Alexion Pharmaceuticals Inc:Submitted New Drug Application (NDA) for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for treatment of hypophosphatasia (HPP), to Japan's Ministry of Health, Labour and Welfare (MHLW).HPP is genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death (1-5).MHLW submission includes positive data from 71 patients with HPP (ranging from newborns to 66 years of age), including Japanese patients, enrolled in three pivotal prospective studies and their extensions, as well as a retrospective natural history study in infants.  Full Article

Alexion Pharmaceuticals Inc appoints new chairman
Thursday, 9 Oct 2014 06:30am EDT 

Alexion Pharmaceuticals Inc:Says Leonard Bell, M.D. has been appointed chairman of the board of directors.Bell, principal founder of Alexion, continues to serve as chief executive officer.  Full Article

Alexion Pharmaceuticals announces the passing of Max Link, Chairman of the company's board of directors
Tuesday, 7 Oct 2014 04:00pm EDT 

Alexion Pharmaceuticals inc:Announces that Max Link, Chairman of the Board of Directors of Alexion, passed away unexpectedly on Oct. 5 while traveling on business.  Full Article

Alexion Pharmaceuticals announces Asfotase Alfa gets Orphan Drug Designation in Japan
Monday, 8 Sep 2014 06:30am EDT 

Alexion Pharmaceuticals Inc:Says Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to asfotase alfa for the treatment of patients with hypophosphatasia (HPP).Asfotase alfa is an investigational, first-in-class targeted enzyme replacement therapy designed to address the underlying cause of HPP.  Full Article

Alexion initiates Multinational Registration Trial of Eculizumab for prevention of delayed graft function (DGF) after Kidney Transplantation
Monday, 25 Aug 2014 06:30am EDT 

Alexion Pharmaceuticals Inc:Initiates dosing in a single, multinational, placebo-controlled clinical trial to evaluate the efficacy and safety of eculizumab (Soliris((reg))) for the prevention of delayed graft function (DGF) after kidney transplantation in adult patients who are at increased risk of DGF.  Full Article

U.S. RESEARCH ROUNDUP-D.R. Horton, Humana, Chicago Bridge & Iron

July 22 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adeptus Health, Chipotle Mexican Grill and Yadkin Financial, on Friday. HIGHLIGHTS * Chicago Bridge & Iron Co : Baird cuts to neutral * D.R. Horton Inc : BofA Merrill cuts to neutral from buy * Humana Inc : Wolfe Research raises to outperform * Community Bank System Inc : Sandler O'Neill cuts to